BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 33683934)

  • 1. Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer.
    Wenzel M; Nocera L; Collà Ruvolo C; Würnschimmel C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
    J Urol; 2021 Jul; 206(1):69-79. PubMed ID: 33683934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding PSA and its derivatives in prediction of tumor volume: Addressing health disparities in prostate cancer risk stratification.
    Chinea FM; Lyapichev K; Epstein JI; Kwon D; Smith PT; Pollack A; Cote RJ; Kryvenko ON
    Oncotarget; 2017 Mar; 8(13):20802-20812. PubMed ID: 28160549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.
    Nocera L; Wenzel M; Collà Ruvolo C; Würnschimmel C; Tian Z; Gandaglia G; Fossati N; Chun FKH; Mirone V; Graefen M; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
    World J Urol; 2022 Jan; 40(1):103-110. PubMed ID: 34436637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis.
    Preisser F; Nazzani S; Bandini M; Marchioni M; Tian Z; Saad F; Chun FK; Shariat SF; Montorsi F; Huland H; Graefen M; Tilki D; Karakiewicz PI
    Int J Urol; 2018 Nov; 25(11):929-936. PubMed ID: 30146729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries.
    Wenzel M; Collà Ruvolo C; Nocera L; Würnschimmel C; Tian Z; Shariat SF; Saad F; Briganti A; Graefen M; Becker A; Mandel P; Chun FKH; Karakiewicz PI
    Cancer Epidemiol; 2021 Oct; 74():101994. PubMed ID: 34364187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
    Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mandel P; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
    World J Urol; 2021 Oct; 39(10):3781-3787. PubMed ID: 33978812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.
    Underwood W; Jackson J; Wei JT; Dunn R; Baker E; Demonner S; Wood DP
    Cancer; 2005 Feb; 103(3):538-45. PubMed ID: 15612083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.
    Lichtensztajn DY; Leppert JT; Brooks JD; Shah SA; Sieh W; Chung BI; Gomez SL; Cheng I
    J Natl Compr Canc Netw; 2018 Nov; 16(11):1353-1360. PubMed ID: 30442735
    [No Abstract]   [Full Text] [Related]  

  • 10. Racial Disparities in the Presentation, Early Definitive Surgical Treatment, and Mortality Among Men Diagnosed with Poorly Differentiated/Undifferentiated Non-metastatic Prostate Cancer in the USA.
    Lediju O; Ikuemonisan J; Salami SS; Adejoro O
    J Racial Ethn Health Disparities; 2019 Apr; 6(2):401-408. PubMed ID: 30506310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database.
    Maurice MJ; Sundi D; Schaeffer EM; Abouassaly R
    J Urol; 2017 Mar; 197(3 Pt 1):627-631. PubMed ID: 27582435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
    Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Würnschimmel C; Wenzel M; Chierigo F; Flammia RS; Tian Z; Saad F; Briganti A; Shariat SF; Suardi N; Terrone C; Gallucci M; Chun FK; Tilki D; Graefen M; Karakiewicz PI
    Int J Urol; 2022 Jan; 29(1):17-24. PubMed ID: 34553428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparities in Hispanic/Latino and non-Hispanic Black men with low-risk prostate cancer and eligible for active surveillance: a population-based study.
    Katz JE; Chinea FM; Patel VN; Balise RR; Venkatramani V; Gonzalgo ML; Ritch C; Pollack A; Parekh DJ; Punnen S
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):533-538. PubMed ID: 29988097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
    Schenk JM; Newcomb LF; Zheng Y; Faino AV; Zhu K; Nyame YA; Brooks JD; Carroll PR; Cooperberg MR; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW
    J Urol; 2020 Apr; 203(4):727-733. PubMed ID: 31651227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
    Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
    J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE.
    Latini DM; Elkin EP; Cooperberg MR; Sadetsky N; Duchane J; Carroll PR
    Cancer; 2006 Feb; 106(4):789-95. PubMed ID: 16400651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population.
    Suresh T; Sharma J; Goel S; Kovac E; Gao Q; Gartrell B
    Clin Genitourin Cancer; 2019 Apr; 17(2):139-144. PubMed ID: 30655076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates.
    Collà Ruvolo C; Stolzenbach LF; Nocera L; Deuker M; Mistretta FA; Luzzago S; Tian Z; Longo N; Graefen M; Chun FKH; Saad F; Briganti A; De Cobelli O; Mirone V; Karakiewicz PI
    Urol Oncol; 2021 Jan; 39(1):74.e1-74.e7. PubMed ID: 32950397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy.
    Leapman MS; Freedland SJ; Aronson WJ; Kane CJ; Terris MK; Walker K; Amling CL; Carroll PR; Cooperberg MR
    J Urol; 2016 Nov; 196(5):1408-1414. PubMed ID: 27352635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.